Arterial Cannula Market – By Size, By Application, By End Use – Global Forecast, 2025 – 2034

Arterial Cannula Market Size

The global arterial cannula market was valued at USD 23.1 million in 2024 and is projected to exhibit 7.3% CAGR from 2025 to 2034. The increasing prevalence of cardiovascular disorders, growing use of respiratory and cardiac support in critical care settings, advancements in cannula design, and the availability of reimbursements and coverage for cardiac and critical care procedures are driving revenue growth in the market.
 

The rising global burden of cardiovascular conditions, such as coronary artery disease, heart failure, and vascular disorders, is driving the demand for arterial cannulas as essential surgical and extracorporeal solutions for managing critical cardiovascular conditions during cardiopulmonary bypass surgeries. According to the World Health Organization's 2023 factsheet, cardiovascular diseases are the leading cause of death worldwide, responsible for approximately 17.9 million deaths annually. Globalization, urbanization, and an aging population are major socio-economic factors contributing to the rise in cardiovascular diseases globally. Consequently, the demand for cardiopulmonary bypass surgeries has increased, further fueling the demand for arterial cannulas worldwide.
 

An arterial cannula is a device used to deliver or remove fluids, such as blood or medications, directly into the arteries. It is widely used in surgeries and critical care settings for procedures such as cardiopulmonary bypass, extracorporeal membrane oxygenation, hemodynamic monitoring, and organ perfusion.
 

Arterial Cannula Market Trends

• Vendors are focusing on improving the design of arterial cannulas to make procedures less invasive, reduce trauma, and enhance patient recovery. New designs feature smoother tips, smaller sizes, and improved flexibility, making insertion easier and causing less damage to blood vessels. This trend aligns with the growing demand for minimally invasive cardiac and extracorporeal procedures, which facilitate quicker recovery and fewer complications.
   
• Also, many arterial cannulas now feature advanced antithrombotic or heparin coatings to reduce the risk of blood clots. These coatings improve compatibility with the body, support smoother blood flow, and reduce complications such as embolism or thrombosis, especially during long-term procedures like ECMO.
   
• Some advanced arterial cannulas now come with built-in sensors that monitor flow, pressure, and oxygen levels in real time. This development helps healthcare providers improve treatment accuracy during critical procedures like ECMO. For instance, Xenios AG, offered by Fresenius Medical, integrates pressure and flow sensors to monitor hemodynamic parameters in real time.
   
• Furthermore, there is a growing trend toward using biodegradable and environmentally sustainable materials for arterial cannulas. These materials maintain performance standards while addressing environmental concerns, particularly in single-use medical devices.
   

Arterial Cannula Market Analysis

Based on size, the market is segmented into 14-16 Fr, 17-19 Fr, 20-22 Fr, 23-25 Fr, 26-28 Fr, 29-31 Fr, 32-34 Fr, and 35-36 Fr. The 20-22 Fr segment dominates the market with a share of 28.4% in 2024.
 

• The dominant share of the 20-22 Fr segment in the market can be attributed to its high adoption rate in a majority of cardiac surgeries and ECMO applications in adult populations, due to its compatibility with adult arterial anatomy.
   
• Also, compared to larger sizes (such as 26-28 Fr), 20-22 Fr arterial cannulas are less invasive, reducing arterial trauma and complications like vascular damage or bleeding during insertion. As a result, 20-22 Fr cannulas are preferred over other sizes in adult patients.
   

Based on application, the arterial cannula market is segmented into cardiopulmonary bypass surgery, extracorporeal membrane oxygenation, and other applications. Cardiopulmonary bypass surgery segment dominates the market with a share of 57.9% in 2024.
 

• Cardiopulmonary bypass is widely used in high-risk heart surgeries, including CABG, valve replacements, and heart transplants. Arterial cannulas are used to redirect blood to an external machine, allowing the heart to temporarily stop. With approximately 400,000 CABG surgeries performed annually (National Library of Medicine, August 2023), the demand for arterial cannulas is rising.
   
• Furthermore, the use of arterial cannulas in cardiopulmonary bypass surgery is well-established, with standardized clinical protocols. This consistency ensures continued demand for arterial cannulas in this segment, contributing to its revenue growth.
   

Based on end user, the arterial cannula market is segmented into hospitals, ambulatory surgical centers, and other end users. The hospitals segment held a dominating share of 73.1% in the market in 2024.
 

• Hospitals, especially those with specialized cardiac surgery or intensive care units, are increasingly using arterial cannulas. These devices are essential for procedures like cardiopulmonary bypass, extracorporeal membrane oxygenation, and major cardiac surgeries. The growing number of heart surgeries, organ transplants, and critical care treatments is driving revenue growth in the hospital segment of the market.
   
• Additionally, hospitals handle large numbers of patients across departments such as cardiology, intensive care, trauma, and emergency medicine. This wide patient base drives the demand for arterial cannulas, particularly in emergencies or critical situations requiring quick surgeries or extracorporeal support, contributing to revenue growth in the hospital segment.
   

In 2024, the U.S. led the North American arterial cannula market, generating a revenue of about USD 8.7 million.
 

• Cardiovascular diseases, including coronary artery disease, heart failure, and stroke, are leading causes of morbidity and mortality in the U.S. As of August 2024, the Centers for Disease Control and Prevention reported that about 1 in 20 U.S. adults aged 20 and older are affected by coronary artery disease. This high prevalence drives the demand for cardiac surgeries and extracorporeal membrane oxygenation (ECMO) procedures, both of which require arterial cannulas, further boosting the market's revenue growth.
   
• Moreover, many leading global manufacturers of arterial cannulas, such as Medtronic, Edwards Lifesciences, and Getinge, are based in the U.S. or have a significant market presence, ensuring a steady supply of high-quality products tailored to meet the needs of the U.S. healthcare system, thereby fostering the country level market growth.
   

The UK is set to see a robust expansion in its arterial cannula market from 2025 to 2034.
 

• The demand for cardiopulmonary bypass surgeries, heart transplants, and ECMO is increasing in the UK due to the high prevalence of cardiovascular diseases like coronary artery disease, heart failure, and stroke. According to the British Heart Foundation, over 39,000 people in the UK died prematurely from conditions like heart attacks and strokes in 2022. This rise in cardiac treatments is driving the need for arterial cannulas across various healthcare facilities.
   
• Additionally, increasing government investments to revolutionize cardiac care delivery are supporting research and development for advanced cardiac care devices, including arterial cannulas, in the UK.
   
• For example, in October 2023, the UK Government, through Integrated Care Systems (ICSs), invited bids for a share of USD 38.2 million (£30 million) to roll out innovative technology in cardiac care. Such initiatives are driving innovations in cardiac care devices and ensuring the easy availability of advanced arterial cannulas in the UK.
   

Japan's arterial cannula market is set for lucrative growth from 2025 to 2034.

• Japan boasts a highly advanced and efficient healthcare system, with many specialized hospitals, research centers, and medical facilities that handle complex surgeries, including cardiopulmonary bypass, heart transplants, and extracorporeal membrane oxygenation.
   
• Moreover, Japan has one of the fastest-aging populations globally, with about 30% of the population aged 65 and older (World Bank, 2023). Older adults are more likely to require heart surgeries, including complex procedures like CPB and ECMO, which depend on arterial cannulas for blood flow management.
   
• Additionally, cardiac diseases rank as the second leading cause of death in Japan, further driving the demand for arterial cannulas in the country.
   

Saudi Arabia's arterial cannula market is expected to witness substantial growth during the forecast period.
 

• Saudi Arabia is significantly investing in its healthcare system under the Vision 2030 plan, focusing on upgrading hospitals, clinics, and specialized medical centers. This development of advanced healthcare facilities is driving the demand for medical devices, including arterial cannulas, which are essential for complex surgeries and critical care.
   
• Saudi Arabia has also become a growing hub for medical tourism in the Middle East, attracting patients from neighbouring countries and beyond. According to Dallah Hospitals, the Middle East region is witnessing a surge in medical tourism, with Saudi Arabia at the forefront of this growth.
   
• The high demand for advanced medical treatments, including cardiovascular care, is contributing to the increased use of arterial cannulas, driving the revenue growth in the market.
   

Arterial Cannula Market Share

The market includes both global medical device companies and regional players, offering a range of products to meet the rising demand for cardiovascular procedures. The competition is driven by technological innovation, product differentiation, and the ability to meet the specific needs of hospitals, clinics, and surgical centers performing cardiopulmonary bypass (CPB), ECMO, and other complex cardiac surgeries. In emerging markets, where affordability is crucial, established manufacturers face challenges in offering cost-effective solutions. Regional players provide lower-cost options, pushing global companies to adjust their pricing strategies while maintaining product quality.
 

Arterial Cannula Market Companies

Some of the eminent market participants operating in the arterial cannula industry include:

• Andocor
• B. Braun
• Becton, Dickinson and Company
• Edward Lifesciences
• Freelife Medical
• Fresenius Medical Care
• Getinge
• ICU Medical
• Kangxin Medical
• LivaNova
• Medtronic
• Nipro Corporation
• Polymedicure
• Surgical Holdings
• Terumo Corporation
   

Arterial Cannula Industry News:

• In January 2022, ICU Medical finalized its acquisition of Smiths Medical, a division of Smiths Group plc. Smiths Medical specializes in syringe and ambulatory infusion devices, vascular access solutions, and vital care products.
   
• In April 2021, Nipro Medical Corporation launched a Vascular Division in the U.S. This division focuses on providing advanced vascular and cardiovascular products and technologies to help clinicians improve patient care with better procedural and imaging solutions.
   

The arterial cannula market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Size

• 14-16 Fr
• 17-19 Fr
• 20-22 Fr
• 23-25 Fr
• 26-28 Fr
• 29-31 Fr
• 32-34 Fr
• 35-36 Fr

Market, By Application

• Cardiopulmonary bypass surgery
• Extracorporeal membrane oxygenation
• Other applications

Market, By End Use

• Hospitals
• Ambulatory surgical centers
• Other end users

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE